Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department

Am J Cardiol. 1995 Aug 15;76(5):396-8. doi: 10.1016/s0002-9149(99)80108-8.


Because time to treatment in AMI is a critical factor in long-term outcome, it is important that complex trials designed to improve reperfusion therapy do not delay the time to treatment. Participation in the TIMI 5 trial did not significantly prolong our door-to-needle time. These results indicate that, if done carefully, complex, labor-intensive studies can be performed within a reasonable time limit. Care should be taken to design protocols incorporating easy drug preparation, informed consent by the ED, and efficiency of trial initiation.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Clinical Trials as Topic*
  • Electrocardiography
  • Emergency Service, Hospital*
  • Heparin / therapeutic use
  • Hirudin Therapy
  • Humans
  • Italy
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / drug therapy*
  • Research
  • Streptokinase / therapeutic use
  • Thrombolytic Therapy*
  • Time Factors
  • United States


  • Heparin
  • Streptokinase